OTS - Eleva Reaches Industrial Production Scale and Prepares for Clinical Development of Factor H
2021. September 14. 10:30
Freiburg, Germany, 14 September, 2021 (APA/OTS) - Eleva, a
manufacturer of superior biologics, is scaling up its production
capacity to 2500 l in state-of-the-art single-use reactors. This
will produce enough factor H to cover all three clinical phases.
Eleva has ordered four more state-of-the-art, 500 l single-use
reactors from Sartorius Stedim Systems. The scale-up will enable
Eleva to enter clinical development of factor H, a key component of
a pathway of the immune system known as alternative complement
pathway.
The complement system enhances (complements) the body's ability
to clear microbes and damaged cells from an organism. Factor H
regulates the activation of that immune response and ensures the
body's own cells are protected. Insufficient regulation of the
complement system leads to excessive inflammation and potential
tissue damage.
Factor H is a complex protein that only Eleva's moss-based
platform has thus far been able to yield in highest - human-like -
quality. Eleva has been able to demonstrate a significant reduction
in tissue damage and inflammation in animal models when its
recombinant factor H was supplemented.
Ralf Smit, CBO: "Not only can we now produce sufficient amounts
of our own drug candidates for all clinical stages, but we are also
in a position to offer production capacity at industrial scale."
While Eleva will be pursuing the development of its own
pipeline products, it is also open for joint projects with other
pharmaceutical companies.
About Eleva
Based in Freiburg, Germany, Eleva develops novel biological
therapies with its pharmaceutical partners. The privately-held
company leverages its unique moss-based production platform to
produce supreme biologics like antibodies, replacement enzymes, or
fusion toxins. Eleva has successfully developed drug candidates
into clinical phases.
Press contact
eleva GmbH
Fabienne Zeitter
pr@elevabiologics.com
Phone: +49 761 470 99 0
www.elevabiologics.com
-------------------------------------------------------------------
Az OTS internetes oldalán található hírek, közlemények, fotók a
forrásmegjelöléssel (OTS) szabadon és korlátozás nélkül
felhasználhatók. Továbbközlés esetén a közzétevő köteles az átvett
anyagot tartalmának torzítása nélkül, félreérthetőséget,
rosszindulatú következtetéseket kizáró, az eredeti
szövegkörnyezetnek megfelelő módon feldolgozni és megjelentetni.
Az OTS hírek nem képezik az MTI hírkiadás részét, az MTI által
szó szerint továbbított tartalomért minden esetben a beadó a
felelős.
© Copyright MTI nonprofit Zrt.
Az OTS szolgáltatással kapcsolatban további információt a
(06-1) 441-9050 telefonszámon vagy a ots@mti.hu elektronikus
levelező címen kaphat.
